Targeted inhibition of IL-4/13 with dupilumab is an effective treatment for eosinophilic dermatosis of hematologic malignancy

Dermatol Ther. 2020 Jul;33(4):e13725. doi: 10.1111/dth.13725. Epub 2020 Jul 3.

Authors

Amrita Goyal¹, Seth Lofgreen¹, Evan Mariash², Andrea Bershow³, Kevin J Gaddis^{1

3}

Affiliations

¹ Department of Dermatology, University of Minnesota, Minneapolis, Minnesota.
² Department of Hematology/Oncology, Minneapolis VA Medical Center, Minneapolis, Minnesota.
³ Department of Dermatology, Minneapolis VA Medical Center, Minneapolis, Minnesota.

PMID: 32558294
DOI: 10.1111/dth.13725

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized
Hematologic Neoplasms*
Humans
Interleukin-13
Interleukin-4
Skin Diseases*

Substances

Antibodies, Monoclonal, Humanized
Interleukin-13
Interleukin-4
dupilumab